The purpose of this study is to determine the effectiveness of EGb 761® (Tanakan®) in Russian patients of middle age and younger, suffering from psycho-emotional symptoms added to cognitive disorders based on the improvement of FAM test (feeling-healthy, activity, mood test) score.

Inclusion Criteria:

• Patients who signed the Informed Consent for participation in the observational study before collection of any information
• Patients who complain of psycho-emotional disturbance (of any intensity)
• Men and women aged 18-45 years, who prescribed to receive Tanakan® for cognitive disorders

Exclusion Criteria:

• Presence of any contraindications listed in the Tanakan® local SmPC (hypersensitivity to any of the components of Tanakan®, pregnancy, lactation, erosive gastritis in acute phase, gastric ulcer and duodenum ulcer in acute phase, acute cerebrovascular accident, acute myocardial infarction, congenital galactosemia, lactase deficiency, glucose-galactose malabsorption, haemolysis)
• Presence of dementia (according to Diagnostic and Statistical Manual of Mental Disorders [DSM IV])
• Disturbance of usual activities of daily living (e.g. self-care)
• Patients taking antipsychotic drugs, antidepressants, tranquillisers and nootropic agents
• Presence of any severe disease or condition which could affect cognitive function (e.g. Parkinson disease, epilepsy, brain inflammatory disease, major depression, recent post-stroke condition, recent brain-trauma etc.);
• Presence of anxiety or depression according to the Hospital Anxiety and Depression Scale (11 points and more).

Middle-age or younger patients with cognitive disorders and psycho-emotional symptoms (principal diagnosis).